ARTICLE | Clinical News
Polaris' ADI-PEG 20 meets in Phase II mesothelioma trial
October 29, 2013 12:46 AM UTC
Polaris Pharmaceuticals Inc. (San Diego, Calif.) said once-weekly intramuscular ADI-PEG 20 plus best supportive care (BSC) for six months met the primary endpoint of improving median progression-free ...